Travere Therapeutics' Filspari boosts revenue with FDA approval, but heavy losses and competitive threats raise concerns for ...

irbesartan. Also, with the removal of the 1.5 gram per gram threshold from the label following full approval in IgA nephropathy, we're hearing that nephrologists are seeking use in a broader ...

In clinical studies of irbesartan there was no relationship between the dosage and the overall frequency of adverse reactions. The rates of serious adverse events were similar for irbesartan (1.0% ...

AT-II-receptor antagonists include losartan, valsartan, irbesartan, candesartan, eprosartan, telmisartan, and tasosartan. Several clinical trials have demonstrated that AT-II-receptor antagonists ...

Ipriflavone can block part of the process that leads to bone loss. Ipriflavone can block part of the process that leads to bone loss. A bone disease that can cause pain (Paget disease). Early ...

Objectives To assess and to compare the effects of losartan and irbesartan on serum uric acid in hypertensive patients with gout. Methods Prospective, randomised, double-blind, cross-over study ...

Say Manufacturers Ready To Bridge Impact Of GSK, Others Exit From Nigeria Nigerian Pharmaceutical companies are beginning to ...

If you have lupus, you’re at a higher risk for a heart attack or stroke. Up to 74% of people with lupus also have high blood pressure. To lower your likelihood of cardiovascular issues and other ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.